Overview Dividends

(MTSR) Metsera, Common Stock - Ratings and Ratios

Exchange: US • Country: United States • Currency: USD • Type: Common Stock • ISIN: (N/A)

Injectable, Oral, Obesity, Peptides

EPS (Earnings per Share)

EPS (Earnings per Share) of MTSR over the last years for every Quarter: "2022-12": null, "2023-12": null, "2024-03": null, "2024-06": null, "2024-09": null, "2024-12": -3.52, "2025-03": -1.03, "2025-06": -0.66, "2025-09": -1.11,
EPS Growth (3y CAGR): 6640.09%
EPS Trend (3y Corr): 72.6%
Qual. Beats: 0

Revenue

Revenue of MTSR over the last years for every Quarter: 2022-12: null, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0,
Revenue Growth (3y CAGR): 0.00%
Qual. Beats: 0
Risk via 10d forecast
Volatility 128%
Value at Risk 5%th 173%
Relative Tail Risk -18.11%
Reward TTM
Sharpe Ratio 1.84
Alpha 277.18
Character TTM
Hurst Exponent 0.599
Beta 1.270
Beta Downside 1.834
Drawdowns 3y
Max DD 59.23%
Mean DD 15.42%
Median DD 14.94%

Description: MTSR Metsera, Common Stock November 07, 2025

Metsera, Inc. (NASDAQ: MTSR) is a clinical-stage biotech founded in 2022 and headquartered in New York. Its core platform centers on injectable and oral nutrient-stimulated hormone analog peptides aimed at obesity, overweight, and related metabolic disorders. The lead candidates are MET-097i and MET-233i for weight reduction, with additional programs (e.g., MET-002, MET-224o, MET-067i, MET-034i, MET-815i) targeting diabetes, obesity, and weight-gain prevention.

Key metrics (as of the latest 10-Q) show a market capitalization of roughly $150 million and a cash runway of about $30 million, sufficient for ~12 months of R&D spend at current burn rates (~$2.5 M / quarter). The obesity therapeutics market is projected to grow > 10 % CAGR through 2030, driven by rising prevalence of metabolic disease and increasing payer willingness to reimburse weight-loss drugs with demonstrated cardiovascular benefit. Within biotech, early-stage peptide programs typically face a 15-20 % probability of reaching market approval, underscoring the high-risk/high-reward profile of Metsera’s pipeline.

If you’re looking for a deeper quantitative assessment of Metsera’s valuation and risk profile, the analysis on ValueRay provides a data-rich perspective worth exploring.

MTSR Stock Overview

Market Cap in USD 7,429m
Sub-Industry Biotechnology
IPO / Inception 2025-01-31
Return 12m vs S&P 500 250%
Analyst Rating 5.0 of 5

MTSR Dividends

Currently no dividends paid

MTSR Growth Ratios

Metric Value
CAGR 3y 458.57%
CAGR/Max DD Calmar Ratio 7.74
CAGR/Mean DD Pain Ratio 29.75
Current Volume 0k
Average Volume 1923.3k

Piotroski VR‑10 (Strict, 0-10) 0.5

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)
FCFTA -0.41 (>2.0%) and ΔFCFTA -13.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.41 (>3.0%) and CFO -231.4m > Net Income -314.4m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 4.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (105.0m) change vs 12m ago 35.53% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2592 (EBITDA TTM -393.9m / Interest Expense TTM 152.0k) >= 6 (WARN >= 3)

Altman Z'' -7.41

(A) 0.62 = (Total Current Assets 461.4m - Total Current Liabilities 108.5m) / Total Assets 567.6m
(B) -0.91 = Retained Earnings (Balance) -518.7m / Total Assets 567.6m
(C) -0.92 = EBIT TTM -394.0m / Avg Total Assets 427.5m
(D) -2.20 = Book Value of Equity -508.1m / Total Liabilities 230.5m
Total Rating: -7.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 49.05

1. Piotroski 0.50pt
2. FCF Yield -3.32%
3. FCF Margin data missing
4. Debt/Equity 0.01
5. Debt/Ebitda 1.13
7. RoE -79.64%
8. Revenue Trend data missing
9. EPS Trend 72.61%

What is the price of MTSR shares?

As of November 21, 2025, the stock is trading at USD 70.50 with a total of 0 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +33.14%, over three months by +119.01% and over the past year by +291.67%.

Is MTSR a buy, sell or hold?

Metsera, Common Stock has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy MTSR.
  • Strong Buy: 4
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MTSR price?

Issuer Target Up/Down from current
Wallstreet Target Price 57 -19.1%
Analysts Target Price 57 -19.1%
ValueRay Target Price 79.8 13.2%

MTSR Fundamental Data Overview November 21, 2025

Market Cap USD = 7.43b (7.43b USD * 1.0 USD.USD)
P/B = 22.0322
Beta = None
Revenue TTM = 0.0 USD
EBIT TTM = -394.0m USD
EBITDA TTM = -393.9m USD
Long Term Debt = 431.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.77m USD (from shortTermDebt, last quarter)
Debt = 2.84m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -445.6m USD (from netDebt column, last quarter)
Enterprise Value = 6.98b USD (7.43b + Debt 2.84m - CCE 448.5m)
Interest Coverage Ratio = -2592 (Ebit TTM -394.0m / Interest Expense TTM 152.0k)
FCF Yield = -3.32% (FCF TTM -231.6m / Enterprise Value 6.98b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 12.0k) / Revenue TTM)
Tobins Q-Ratio = 12.30 (Enterprise Value 6.98b / Total Assets 567.6m)
Interest Expense / Debt = 0.28% (Interest Expense 8000 / Debt 2.84m)
Taxrate = -0.0% (0.0 / -116.2m)
NOPAT = -394.0m (EBIT -394.0m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 4.25 (Total Current Assets 461.4m / Total Current Liabilities 108.5m)
Debt / Equity = 0.01 (Debt 2.84m / totalStockholderEquity, last quarter 337.2m)
Debt / EBITDA = 1.13 (negative EBITDA) (Net Debt -445.6m / EBITDA -393.9m)
Debt / FCF = 1.92 (negative FCF - burning cash) (Net Debt -445.6m / FCF TTM -231.6m)
Total Stockholder Equity = 394.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.39% (Net Income -314.4m / Total Assets 567.6m)
RoE = -79.64% (Net Income TTM -314.4m / Total Stockholder Equity 394.8m)
RoCE = -99.68% (out of range, set to none) (EBIT -394.0m / Capital Employed (Equity 394.8m + L.T.Debt 431.0k))
RoIC = -149.0% (out of range, set to none) (NOPAT -394.0m / Invested Capital 264.4m)
WACC = 10.70% (E(7.43b)/V(7.43b) * Re(10.70%) + D(2.84m)/V(7.43b) * Rd(0.28%) * (1-Tc(-0.0)))
Discount Rate = 10.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 45.01%
Fair Price DCF = unknown (Cash Flow -231.6m)
EPS Correlation: 72.61 | EPS CAGR: 6640 % | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0

Additional Sources for MTSR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle